Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma

Background: Diffuse large B-cell lymphoma (DLBCL), which is considered to be the most common subtype of lymphoma, is an aggressive tumor. Necroptosis, a novel type of programmed cell death, plays a bidirectional role in tumors and participates in the tumor microenvironment to influence tumor develop...

Full description

Bibliographic Details
Main Authors: Yu-Biao Pan, Wei Wang, Hong-Kai Cai, Jia Zhang, Ya Teng, Jiji Xue, Min Zhu, Wen-Da Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.911443/full
_version_ 1811308780236832768
author Yu-Biao Pan
Yu-Biao Pan
Wei Wang
Wei Wang
Hong-Kai Cai
Hong-Kai Cai
Jia Zhang
Jia Zhang
Ya Teng
Jiji Xue
Min Zhu
Wen-Da Luo
Wen-Da Luo
Wen-Da Luo
author_facet Yu-Biao Pan
Yu-Biao Pan
Wei Wang
Wei Wang
Hong-Kai Cai
Hong-Kai Cai
Jia Zhang
Jia Zhang
Ya Teng
Jiji Xue
Min Zhu
Wen-Da Luo
Wen-Da Luo
Wen-Da Luo
author_sort Yu-Biao Pan
collection DOAJ
description Background: Diffuse large B-cell lymphoma (DLBCL), which is considered to be the most common subtype of lymphoma, is an aggressive tumor. Necroptosis, a novel type of programmed cell death, plays a bidirectional role in tumors and participates in the tumor microenvironment to influence tumor development. Targeting necroptosis is an intriguing direction, whereas its role in DLBCL needs to be further discussed.Methods: We obtained 17 DLBCL-associated necroptosis-related genes by univariate cox regression screening. We clustered in GSE31312 depending on their expressions of these 17 genes and analyzed the differences in clinical characteristics between different clusters. To investigate the differences in prognosis across distinct clusters, the Kaplan-Meier method was utilized. The variations in the tumor immune microenvironment (TME) between distinct necroptosis-related clusters were investigated via “ESTIMATE”, “Cibersort” and single-sample geneset enrichment analysis (ssGSEA). Finally, we constructed a 6-gene prognostic model by lasso-cox regression and subsequently integrated clinical features to construct a prognostic nomogram.Results: Our analysis indicated stable but distinct mechanism of action of necroptosis in DLBCL. Based on necroptosis-related genes and cluster-associated genes, we identified three groups of patients with significant differences in prognosis, TME, and chemotherapy drug sensitivity. Analysis of immune infiltration in the TME showed that cluster 1, which displayed the best prognosis, was significantly infiltrated by natural killer T cells, dendritic cells, CD8+ T cells, and M1 macrophages. Cluster 3 presented M2 macrophage infiltration and the worst prognosis. Importantly, the prognostic model successfully differentiated high-risk from low-risk patients, and could forecast the survival of DLBCL patients. And the constructed nomogram demonstrated a remarkable capacity to forecast the survival time of DLBCL patients after incorporating predictive clinical characteristics.Conclusion: The different patterns of necroptosis explain its role in regulating the immune microenvironment of DLBCL and the response to R-CHOP treatment. Systematic assessment of necroptosis patterns in patients with DLBCL will help us understand the characteristics of tumor microenvironment cell infiltration and aid in the development of tailored therapy regimens.
first_indexed 2024-04-13T09:29:26Z
format Article
id doaj.art-cfaa792e418847f9af213b02bd998550
institution Directory Open Access Journal
issn 1664-8021
language English
last_indexed 2024-04-13T09:29:26Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Genetics
spelling doaj.art-cfaa792e418847f9af213b02bd9985502022-12-22T02:52:19ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-08-011310.3389/fgene.2022.911443911443Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphomaYu-Biao Pan0Yu-Biao Pan1Wei Wang2Wei Wang3Hong-Kai Cai4Hong-Kai Cai5Jia Zhang6Jia Zhang7Ya Teng8Jiji Xue9Min Zhu10Wen-Da Luo11Wen-Da Luo12Wen-Da Luo13Taizhou Hospital of Zhejiang Province, Zhejiang University, Hangzhoua, ChinaDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province, Zhejiang University, Hangzhoua, ChinaDepartment of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaTaizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, ChinaBackground: Diffuse large B-cell lymphoma (DLBCL), which is considered to be the most common subtype of lymphoma, is an aggressive tumor. Necroptosis, a novel type of programmed cell death, plays a bidirectional role in tumors and participates in the tumor microenvironment to influence tumor development. Targeting necroptosis is an intriguing direction, whereas its role in DLBCL needs to be further discussed.Methods: We obtained 17 DLBCL-associated necroptosis-related genes by univariate cox regression screening. We clustered in GSE31312 depending on their expressions of these 17 genes and analyzed the differences in clinical characteristics between different clusters. To investigate the differences in prognosis across distinct clusters, the Kaplan-Meier method was utilized. The variations in the tumor immune microenvironment (TME) between distinct necroptosis-related clusters were investigated via “ESTIMATE”, “Cibersort” and single-sample geneset enrichment analysis (ssGSEA). Finally, we constructed a 6-gene prognostic model by lasso-cox regression and subsequently integrated clinical features to construct a prognostic nomogram.Results: Our analysis indicated stable but distinct mechanism of action of necroptosis in DLBCL. Based on necroptosis-related genes and cluster-associated genes, we identified three groups of patients with significant differences in prognosis, TME, and chemotherapy drug sensitivity. Analysis of immune infiltration in the TME showed that cluster 1, which displayed the best prognosis, was significantly infiltrated by natural killer T cells, dendritic cells, CD8+ T cells, and M1 macrophages. Cluster 3 presented M2 macrophage infiltration and the worst prognosis. Importantly, the prognostic model successfully differentiated high-risk from low-risk patients, and could forecast the survival of DLBCL patients. And the constructed nomogram demonstrated a remarkable capacity to forecast the survival time of DLBCL patients after incorporating predictive clinical characteristics.Conclusion: The different patterns of necroptosis explain its role in regulating the immune microenvironment of DLBCL and the response to R-CHOP treatment. Systematic assessment of necroptosis patterns in patients with DLBCL will help us understand the characteristics of tumor microenvironment cell infiltration and aid in the development of tailored therapy regimens.https://www.frontiersin.org/articles/10.3389/fgene.2022.911443/fulldiffuse large B-cell lymphomanecroptosisprognosisTMEimmunization
spellingShingle Yu-Biao Pan
Yu-Biao Pan
Wei Wang
Wei Wang
Hong-Kai Cai
Hong-Kai Cai
Jia Zhang
Jia Zhang
Ya Teng
Jiji Xue
Min Zhu
Wen-Da Luo
Wen-Da Luo
Wen-Da Luo
Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
Frontiers in Genetics
diffuse large B-cell lymphoma
necroptosis
prognosis
TME
immunization
title Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
title_full Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
title_fullStr Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
title_full_unstemmed Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
title_short Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma
title_sort integrative analysis of a necroptosis related gene signature of clinical value and heterogeneity in diffuse large b cell lymphoma
topic diffuse large B-cell lymphoma
necroptosis
prognosis
TME
immunization
url https://www.frontiersin.org/articles/10.3389/fgene.2022.911443/full
work_keys_str_mv AT yubiaopan integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT yubiaopan integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT weiwang integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT weiwang integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT hongkaicai integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT hongkaicai integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT jiazhang integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT jiazhang integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT yateng integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT jijixue integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT minzhu integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT wendaluo integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT wendaluo integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma
AT wendaluo integrativeanalysisofanecroptosisrelatedgenesignatureofclinicalvalueandheterogeneityindiffuselargebcelllymphoma